299 related articles for article (PubMed ID: 33888083)
21. Clinicopathological characteristics and prognosis of hepatitis B associated membranous nephropathy and idiopathic membranous nephropathy complicated with hepatitis B virus infection.
Wang R; Wu Y; Zheng B; Zhang X; An D; Guo N; Wang J; Guo Y; Tang L
Sci Rep; 2021 Sep; 11(1):18407. PubMed ID: 34526634
[TBL] [Abstract][Full Text] [Related]
22. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
23. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
24. Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy.
Shang SL; Cai GY; Duan SW; Li P; Li QG; Chen XM
BMC Nephrol; 2018 Jul; 19(1):182. PubMed ID: 30021637
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
Chen Y; Deng Y; Ni Z; Chen N; Chen X; Shi W; Zhan Y; Yuan F; Deng W; Zhong Y
Am J Kidney Dis; 2013 Dec; 62(6):1068-76. PubMed ID: 23810688
[TBL] [Abstract][Full Text] [Related]
27. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
[TBL] [Abstract][Full Text] [Related]
28. Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy.
Ji FP; Wen L; Zhang YP; Liu EP; Wen JG
Int Urol Nephrol; 2022 Jun; 54(6):1287-1294. PubMed ID: 34585312
[TBL] [Abstract][Full Text] [Related]
29. Response to immunosuppressive therapy in PLA
Wang J; Xie Q; Sun Z; Xu N; Li Y; Wang L; Liu S; Xue J; Hao CM
BMC Nephrol; 2017 Jul; 18(1):227. PubMed ID: 28693446
[TBL] [Abstract][Full Text] [Related]
30. Smoking is a risk factor for the progression of idiopathic membranous nephropathy.
Yamaguchi M; Ando M; Yamamoto R; Akiyama S; Kato S; Katsuno T; Kosugi T; Sato W; Tsuboi N; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
PLoS One; 2014; 9(6):e100835. PubMed ID: 24964146
[TBL] [Abstract][Full Text] [Related]
31. Retrospective analysis of
Guo Y; Guo N; Wang J; Wang R; Tang L
Ren Fail; 2021 Dec; 43(1):729-736. PubMed ID: 33904354
[TBL] [Abstract][Full Text] [Related]
32. Acute kidney injury in idiopathic membranous nephropathy with nephrotic syndrome.
Chen T; Zhou Y; Chen X; Chen B; Pan J
Ren Fail; 2021 Dec; 43(1):1004-1011. PubMed ID: 34157952
[TBL] [Abstract][Full Text] [Related]
33. Effect of Glomerular Mannose-Binding Lectin Deposition on the Prognosis of Idiopathic Membranous Nephropathy.
Zhang Y; Liu Y; Liang L; Liu L; Tang X; Tang L; Chen P; Chen J; Wang Z; Cao W; Chen Q; Zhao N; Xu D
Kidney Blood Press Res; 2020; 45(5):713-726. PubMed ID: 32894840
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of tacrolimus-based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study.
Zhang XJ; Ji CF; Yuan JZ; Wang L; Zhang J; Fang W; Bai DF; Hu Z
Kaohsiung J Med Sci; 2019 Oct; 35(10):633-639. PubMed ID: 31225949
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes of initial therapy for idiopathic membranous nephropathy.
Sato M; Takei T; Moriyama T; Itabashi M; Nitta K
Clin Exp Nephrol; 2017 Oct; 21(5):842-851. PubMed ID: 27999961
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy.
Zou H; Jiang F; Xu G
Ren Fail; 2019 Nov; 41(1):673-681. PubMed ID: 31354007
[No Abstract] [Full Text] [Related]
37. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort.
du Buf-Vereijken PW; Feith GW; Hollander D; Gerlag PG; Wirtz JJ; Noordzij TC; Wetzels JF;
QJM; 2004 Jun; 97(6):353-60. PubMed ID: 15152109
[TBL] [Abstract][Full Text] [Related]
38. Idiopathic membranous nephropathy in older patients: Clinical features and outcomes.
Choi JY; Chin HJ; Lee H; Bae EH; Chang TI; Lim JH; Jung HY; Cho JH; Kim CD; Kim YL; Park SH;
PLoS One; 2020; 15(10):e0240566. PubMed ID: 33035278
[TBL] [Abstract][Full Text] [Related]
39. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy.
Goumenos DS; Kalliakmani P; Tsakas S; Sotsiou F; Vlachojannis JG
Clin Nephrol; 2004 Jan; 61(1):17-24. PubMed ID: 14964453
[TBL] [Abstract][Full Text] [Related]
40. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
Ruggenenti P; Mosconi L; Vendramin G; Moriggi M; Remuzzi A; Sangalli F; Remuzzi G
Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
